WealthPLAN Partners LLC Has $2.61 Million Holdings in Pfizer Inc. (NYSE:PFE)


Share on StockTwits

WealthPLAN Partners LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 74,914 shares of the biopharmaceutical company’s stock after selling 1,803 shares during the period. WealthPLAN Partners LLC’s holdings in Pfizer were worth $2,613,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. HNP Capital LLC raised its holdings in Pfizer by 1.7% during the 3rd quarter. HNP Capital LLC now owns 16,689 shares of the biopharmaceutical company’s stock worth $607,000 after buying an additional 275 shares during the period. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC grew its stake in Pfizer by 2.8% during the 3rd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 10,195 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 277 shares in the last quarter. Redhawk Wealth Advisors Inc. grew its stake in Pfizer by 3.7% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 7,710 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 278 shares in the last quarter. Weaver Consulting Group grew its stake in Pfizer by 5.1% during the 4th quarter. Weaver Consulting Group now owns 5,791 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 281 shares in the last quarter. Finally, Day & Ennis LLC grew its stake in Pfizer by 1.2% during the 3rd quarter. Day & Ennis LLC now owns 23,589 shares of the biopharmaceutical company’s stock valued at $866,000 after acquiring an additional 283 shares in the last quarter. Hedge funds and other institutional investors own 67.36% of the company’s stock.

Shares of PFE stock traded down $0.52 during trading hours on Tuesday, reaching $33.74. 817,955 shares of the company’s stock were exchanged, compared to its average volume of 35,504,273. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $43.08. The stock has a market capitalization of $187.54 billion, a P/E ratio of 22.10, a P/E/G ratio of 2.79 and a beta of 0.70. The business has a fifty day moving average price of $35.94 and a 200-day moving average price of $37.10. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the firm earned $0.55 earnings per share. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.89 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 5th. Investors of record on Friday, January 29th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.62%. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Thursday, January 28th. Pfizer’s dividend payout ratio is presently 52.88%.

Several equities analysts have weighed in on PFE shares. SVB Leerink lowered their target price on Pfizer from $44.00 to $40.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 3rd. Sanford C. Bernstein started coverage on Pfizer in a research note on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price target for the company. DZ Bank reissued a “buy” rating and issued a $41.00 price target on shares of Pfizer in a research note on Wednesday, February 3rd. Morgan Stanley lowered their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Friday, January 29th. Finally, The Goldman Sachs Group set a $40.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Thursday, January 21st. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $39.38.

Pfizer Company Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Article: Marijuana Stocks Investing Considerations

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.